Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (09) : 982-986     DOI: 10.3971/j.issn.1000-8578.2022.22.0064
|
Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer
CHEN Zegang1, WANG Yongbing1, OU Tao2
1. Department of Oncology, Chongqing Liangping District People’s Hospital, Chongqing 405200, China; 2. Center of Cancer Radiotherapy, Chongqing University Cancer Hospital, Chongqing 400000, China
Download: PDF(10207 KB)   ( 26 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Borderline resectable pancreatic ductal adenocarcinoma accounts for approximately 20% of newly diagnosed pancreatic cancer patients. This type of adenocarcinoma is between resectable and unresectable. It has a high degree of heterogeneity and features in anatomy, biology, and physical condition. The biological characteristics of invasiveness determine that, rather than direct surgery, neoadjuvant therapy should be primarily given to patients to achieve R0 resection and avoid early postoperative recurrence. However, this treatment model is still controversial. According to the latest research on this topic, the full text summarizes the definition of BR-PDAC, resectable evaluation, neoadjuvant treatment selection and evaluation, surgical results after neoadjuvant therapy, and the efficacy of adjuvant therapy after neoadjuvant therapy.
Keywords Pancreatic ductal adenocarcinoma      Borderline resectable pancreatic cancer      Neoadjuvant therapy      Operation      Chemotherapy      Radiotherapy     
ZTFLH:  R735.9  
Fund:Chongqing Science and Health Joint Medical Research Project (No. 2021MSXM289)
Issue Date: 15 September 2022
 Cite this article:   
CHEN Zegang,WANG Yongbing,OU Tao. Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 982-986.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.22.0064
http://www.zlfzyj.com/EN/Y2022/V49/I09/982
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
CHEN Zegang
WANG Yongbing
OU Tao
[1] Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer[J]. Lancet,<br /> 2020, 395(10242): 2008-2020.<br /> [2] Demir IE, J?ger C, Schlitter AM, et al. R0 Versus R1 Resection<br /> Matters after Pancreaticoduodenectomy, and Less after Distal or<br /> Total Panctomy for Pancreatic Cancer[J]. Ann Surg, 2018,<br /> 268(6): 1058-1068.<br /> [3] Kimura N, Yamada S, Takami H, et al. Optimal Preoperative<br /> Multidisciplinary Treatment in Borderline Resectable Pancreatic<br /> Cancer[J]. Cancers (Basel), 2020, 13(1): 36.<br /> [4] Gillen S, Schuster T, Meyer zum Büschenfelde C, et al.<br /> Preoperative/neoadjuvant therapy in pancreatic cancer: a<br /> systematic review and metaanalysis of response and resection<br /> percentages[J]. PLoS Med, 2010, 7(4): e1000267.<br /> [5] Katz MH, Shi Q, Ahmad SA, et al. Preoperative Modified<br /> FOLFIRINOX Treatment Followed by Capecitabine-Based<br /> Chemoradiation for Borderline Resectable Pancreatic Cancer:<br /> Alliance for Clinical Trials in Oncology Trial A021101[J]. JAMA<br /> Surg, 2016, 151(8): e161137.<br /> [6] Isaji S, Mizuno S, Windsor JA, et al. International consensus on<br /> definition and criteria of borderline resectable pancreatic ductal<br /> adenocarcinoma 2017[J]. Pancreatology, 2018, 18(1): 2-11.<br /> [7] Yamada S, Takami H, Sonohara F, et al. Effects of duration of<br /> initial treatment on postoperative complications in pancreatic<br /> cancer[J]. J Hepatobiliary Pancreat Sci, 2019, 26(6): 235-241.<br /> [8] Versteijne E, Vogel JA, Besselink MG, et al. Meta-analysis<br /> comparing upfront surgery with neoadjuvant treatment in patients<br /> with resectable or borderline resectable pancreatic cancer[J]. Br J<br /> Surg, 2018, 105(8): 946-958.<br /> [9] Paniccia A, Hosokawa P, Henderson W, et al. Characteristics of<br /> 10-year survivors of pancreatic ductal adenocarcinoma[J]. JAMA<br /> Surg, 2015, 150(8): 701-710.<br /> [10] Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or<br /> gemcitabine as adjuvant therapy for pancreatic cancer[J]. N Engl J<br /> Med, 2018, 379(25): 2395-2406.<br /> [11] Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX<br /> in patients with borderline resectable pancreatic cancer: a<br /> systematic review and patient-level meta-analysis[J]. J Natl<br /> Cancer Inst, 2019, 111(8): 782-794.<br /> [12] van der Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative<br /> biliary drainage for cancer of the head of the pancreas[J]. N Engl<br /> J Med, 2010, 362(2): 129-137.<br /> [13] Kunzmann V, Siveke JT, Algül H, et al. Nab-paclitaxel plus<br /> gemcitabine versus nab-paclitaxel plus gemcitabine followed<br /> by FOLFIRINOX induction chemotherapy in locally advanced<br /> pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre,<br /> randomised, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2021,<br /> 6(2): 128-138.<br /> [14] Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus<br /> gemcitabine for metastatic pancreatic cancer[J]. N Engl J<br /> Med, 2011, 364(19): 1817-1825.<br /> [15]Paniccia A, Edil BH, Schulick RD, et al. Neoadjuvant<br /> FOLFIRINOX application in borderline resectable pancreatic<br /> adenocarcinoma: a retrospective cohort study[J]. Medicine<br /> (Baltimore), 2014, 93(27): e198.<br /> [16] Choi YJ, Byun Y, Kang JS, et al. Comparison of Clinical<br /> Outcomes of Borderline Resectable Pancreatic Cancer According<br /> to the Neoadjuvant Chemo-Regimens: Gemcitabine versus<br /> FOLFIRINOX[J]. Gut Liver, 2021, 15(3): 466-475.<br /> [17]Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant<br /> chemoradiotherapy and chemotherapy in resectable pancreatic<br /> cancer: a randomised controlled trial[J]. Lancet, 2001, 358(9293):<br /> <p> 1576-1585. </p> <p> [18] Chapman BC, Gleisner A, Rigg D, et al. Perioperative outcomes<br /> and survival following neoadjuvant stereotactic body radiation<br /> therapy (SBRT) versus intensity-modulated radiation therapy<br /> (IMRT) in pancreatic adenocarcinoma[J]. J Surg Oncol, 2018,<br /> 117(5): 1073-1083.<br /> [19] Stokes JB, Nolan NJ, Stelow EB, et al. Preoperative capecitabine<br /> and concurrent radiation for borderline resectable pancreatic<br /> cancer[J]. Ann Surg Oncol, 2011, 18(3): 619-627.<br /> [20] Takai S, Satoi S, Yanagimoto H, et al. Neoadjuvant chemoradiation<br /> in patients with potentially resectable pancreatic cancer[J]. Pancre<br /> as, 2008, 36(1): e26-e32.<br /> [21] Cho IR, Chung MJ, Bang S, et al. Gemcitabine based neoadjuvant<br /> chemoradiotherapy therapy in patients with borderline resectable<br /> pancreatic cancer[J]. Pancreatology, 2013, 13(5): 539-543.<br /> [22] Katz MH, Marsh R, Herman JM, et al. Borderline resectable<br /> pancreatic cancer:need for standardization and methods for<br /> optimal clinical trial design[J]. Ann Surg Oncol, 2013, 20(8):<br /> 2787-2795.<br /> [23] Christians KK, Tsai S, Mahmoud A, et al. Neoadjuvant<br /> FOLFIRINOX for borderline resectable pancreas cancer: a new<br /> treatment paradigm?[J]. Oncologist, 2014, 19(3): 266-274.<br /> [24] Dhir M, Malhotra GK, Sohal DPS, et al. Neoadjuvant treatment of<br /> pancreatic adenocarcinoma: a systematic review and meta-analysis<br /> of 5520 patients[J]. World J Surg Oncol, 2017, 15(1): 183.<br /> [25] Nappo G, Donisi G, Zerbi A. Borderline resectable pancreatic<br /> cancer: Certainties and controversies[J]. World J Gastrointest<br /> Surg, 2021, 13(6): 516-528.<br /> [26] Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic<br /> Adenocarcinoma, Version 2.2021, NCCN Clinical Practice<br /> Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2021, 19(4):<br /> 439-457.<br /> [27] 中华医学会外科学分会胰腺外科学组. 中国胰腺癌诊治指南<br /> (2021)[J]. 中华消化外科杂志, 2021, 59(7): 561-577. [Pancreatic<br /> Surgery Group, Branch of Surgery, Chinese Medical Association.<br /> Guidelines for the diagnosis and treatment of pancreatic cancer in<br /> China(2021)[J]. Zhonghua Xiao Hua Wai Ke Za Zhi, 2021, 59(7):<br /> 561-577.]<br /> [28] Cao F, Li J, Li A, et al. Prognostic significance of positive<br /> peritoneal cytology in resectable pancreatic cancer: a systemic<br /> review and meta-analysis[J]. Oncotarget, 2017, 8(9): 15004-<br /> 15013.<br /> [29] Toesca DAS, Koong AJ, Poultsides GA, et al. Management of<br /> borderline resectable pancreatic cancer[J]. Int J Radiat Oncol Biol<br /> Phys, 2018, 100(5): 1155-1174.<br /> [30] Ferrone CR, Marchegiani G, Hong TS, et al. Radiological<br /> and surgical implications of neoadjuvant treatment with<br /> FOLFIRINOX for locally advanced and borderline resectable<br /> pancreatic cancer[J]. Ann Surg, 2015, 261(1): 12-17.<br /> [31] Katz MH, Pisters PW, Evans DB, et al. Borderline resectable<br /> pancreatic cancer: the importance of this emerging stage of<br /> disease[J]. J Am Coll Surg, 2008, 206(5): 833-846.<br /> [32] Katz MH, Fleming JB, Bhosale P, et al. Response of borderline<br /> resectable pancreatic cancer to neoadjuvant therapy is not<br /> reflected by radiographic indicators[J]. Cancer, 2012, 118(23):<br /> 5749-5756.<br /> [33] Kaufmann B, Hartmann D, D'Haese JG, et al. Neoadjuvant<br /> Treatment for Borderline Resectable Pancreatic Ductal<br /> Adenocarcinoma[J]. Dig Surg, 2019, 36(6): 455-461.<br /> [34] Panda A, Garg I, Truty MJ, et al. Borderline Resectable and<br /> Locally Advanced Pancreatic Cancer:FDG PET/MRI and CT<br /> Tumor Metrics for Assessment of Pathologic Response to<br /> Neoadjuvant Therapy and Prediction of Survival[J]. AJR Am J<br /> Roentgenol, 2021, 217(3): 730-740.<br /> [35] Hank T, Sandini M, Ferrone CR, et al. Association Between<br /> Pancreatic Fistula and Long-term Survival in the Era of<br /> Neoadjuvant Chemotherapy[J]. JAMA Surg, 2019, 154(10):<br /> 943-951.<br /> [36] Ecker BL, McMillan MT, Allegrini V, et al. Risk Factors<br /> and Mitigation Strategies for Pancreatic Fistula After Distal<br /> Panctomy: Analysis of 2026 Resections From the<br /> International, Multi-institutional Distal Panctomy Study<br /> Group[J]. Ann Surg, 2019, 269(1): 143-149.<br /> [37] Takahashi H, Ogawa H, Ohigashi H, et al. Preoperative<br /> chemoradiation reduces the risk of pancreatic fistula after distal<br /> panctomy for pancreatic adenocarcinoma[J]. Surgery, 2011,<br /> 150(3): 547-556.<br /> [38] Verma V, Li J, Lin C. Neoadjuvant Therapy for Pancreatic Cancer:<br /> Systematic Review of Postoperative Morbidity, Mortality, and<br /> Complications[J]. Am J Clin Oncol, 2016, 39(3): 302-313.<br /> [39] Kamarajah SK, Bundred JR, Boyle C, et al. Impact of neoadjuvant<br /> therapy on post-operative pancreatic fistula: a systematic review<br /> and meta-analysis[J]. ANZ J Surg, 2020, 90(11): 2201-2210.<br /> [40] Pietrasz D, Marthey L, Wagner M, et al. Pathologic Major<br /> Response After FOLFIRINOX is Prognostic for Patients<br /> Secondary Resected for Borderline or Locally Advanced<br /> Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective,<br /> Multicentric Cohort[J]. Ann Surg Oncol, 2015, 22 Suppl 3:<br /> S1196-S1205.<br /> [41] Roland CL, Katz MH, Tzeng CW, et al. The Addition of<br /> Postoperative Chemotherapy is Associated with Improved<br /> Survival in Patients with Pancreatic Cancer Treated with<br /> Preoperative Therapy[J]. Ann Surg Oncol, 2015, 22 Suppl 3:<br /> S1221-S1228.<br /> [42] Barnes CA, Krepline AN, Aldakkak M, et al. Is Adjuvant Therapy<br /> Necessary for All Patients with Localized Pancreatic Cancer<br /> Who Have Received Neoadjuvant Therapy?[J]. J Gastrointest<br /> Surg, 2017, 21(11): 1793-1803.<br /> [43] van Roessel S, Veldhuisen E, Klompmaker S, et al. Evaluation<br /> of Adjuvant Chemotherapy in Patients With Resected Pancreatic<br /> Cancer After Neoadjuvant FOLFIRINOX Treatment[J]. JAMA<br /> Oncol, 2020, 6(11): 1733-1740. </p>
Related articles from Frontiers Journals
[1] WANG Yu, KANG Hua. Assessment and Management of Axillary Lymph Nodes for Breast Cancer Under Concept of Precision Therapy[J]. Cancer Research on Prevention and Treatment, 2022, 49(10): 1003-1009.
[2] HAO Xiuxiu, FANG Wentao, GU Zhitao. Value of Postoperative Radiotherapy in Treatment of Completely Resected Thymic Tumors[J]. Cancer Research on Prevention and Treatment, 2022, 49(10): 1010-1014.
[3] XIONG Yudi, ZHANG Xue, ZOU Ning, MOU Jingjing, LI Benhui, CHEN Weidong, LIAO Lingxia, ZHANG Jiucheng. A Prospective PhaseⅠ Clinical Study of Docetaxel with Concurrent Late-course Hyperfractionated Radiotherapy After Breast-conserving Surgery for Stage T1-T2 Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(10): 1054-1058.
[4] WU Zhuochao, HUANG Zhaohui, . Advances in Tumor-associated Macrophages in Cancer Radiotherapy[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 870-874.
[5] MAO Wanli, RAN Li, LI Jiehui, LI Fenghu, CHANG Jianying, MU Junyu, MEI Fan, HU Lili, DU Yanjun, TIAN Xue, QIN Yao, YIN Shuishui. Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 937-943.
[6] KANG Yikun, YUAN Peng. Advances in Treatment of Triple Negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 812-819.
[7] WEI Zongjie, KUANG Youlin, CHEN Yong, WANG Lu, CHEN Xiao, GOU Xin. Efficacy and Adverse Reaction of Tislelizumab Combined with Chemotherapy on Urothelial Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 698-702.
[8] CHEN Bojin, HU Xingyi, ZHAO Jingwen, ZHENG Aihong. Current Status of Immunotherapy in Neoadjuvant Therapy for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 727-732.
[9] SUN Junzhao, CHENG Gang, ZHANG Jianning. Advances in Treatment of Brain Metastasis from Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 522-527.
[10] JIN Long, XU Dameng, ZHOU Yuanyuan, YU Jiao. Application of 18F-FDG PET-CT Simulation Localization in Radiotherapy of Recurrent Abdominal and Pelvic Tumors[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 453-458.
[11] LI Yingying, LI Jinhu, LIU Xiaodong. Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors in Treatment of Glioblastoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 490-495.
[12] XIE Zhanghong, HUA Qingquan. Research Progress of Ferroptosis in Head and Neck Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 282-287.
[13] WANG Jun, JIN Heiying. Several Critical Issues of Low Rectal Cancer Surgery[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 288-293.
[14] FAN Bingjie, CHANG Yu, LIU Xiyang, ZHANG Mingzhi, ZHANG Lei. Effects of Chemoradiotherapy Versus Chemotherapy Alone on Survival of Patients with Primary Mediastinal Large B-cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(03): 205-212.
[15] JIANG Yujuan, ZHOU Sicheng, PEI Wei, LIANG Jianwei, ZHOU Zhixiang. Advances in Neoadjuvant Therapy for Locally Advanced Rectal Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(03): 235-239.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed